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Abstract
Background: People with type 2 diabetes mellitus (T2DM) generally spend a large amount of time sitting. This
increases their risk of cardiovascular disease, premature mortality, diabetes-related complications and mental health
problems. There is a paucity of research that has evaluated interventions aimed at reducing and breaking up sitting
in people with T2DM. The primary aim of this study is to assess the feasibility of delivering and evaluating a tailored
intervention to reduce and break up sitting in ambulatory adults with T2DM.
Methods: This is a mixed-methods randomised controlled feasibility trial. Participants (n=70) with T2DM aged 18-85
years who sit ≥7 h/day and are able to ambulate independently will be randomly allocated to receive the REgulate
your SItting Time (RESIT) intervention or usual care (control group) for 24 weeks. RESIT is a person-focused
intervention that delivers a standardised set of behaviour change techniques to the participants, but the mode
through which they are delivered can vary depending on the tools selected by each participant. The intervention
includes an online education programme, health coach support, and a range of self-selected tools (smartphone
apps, computer-prompt software, and wearable devices) that deliver behaviour change techniques such as self-
monitoring of sitting and providing prompts to break up sitting. Measures will be taken at baseline, 12 and 24
weeks. Eligibility, recruitment, retention and data completion rates will be used to assess trial feasibility. Sitting,
standing and stepping will be measured using a thigh-worn activity monitor. Cardiometabolic health, physical
function, psychological well-being, sleep and musculoskeletal symptoms will also be assessed. A process evaluation
will be conducted including evaluation of intervention acceptability and fidelity.
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Discussion: This study will identify the feasibility of delivering a tailored intervention to reduce and break up sitting
in ambulatory adults with T2DM and evaluating it through a randomised controlled trial (RCT) design. The findings
will inform a fully powered RCT to evaluate the effectiveness of the intervention.
Trial registration: ISRCTN, ISRCTN14832389; Registered 6 August 2020.
Keywords: Sedentary behaviour, Prolonged sitting, Physical activity, Behaviour change, Diabetes, activPAL
Introduction
There are more than 4 million people with type 2 dia-
betes mellitus (T2DM) in the UK, costing the National
Health Service (NHS) 10% of its annual budget [1].
People with T2DM have a high risk of cardiovascular
disease (CVD), early death, poor psychological well-
being and a burden of diabetes-related complications,
e.g. neuropathy, nephropathy and retinopathy [2, 3]. Gly-
caemic control is important for reducing the onset of
these secondary outcomes [4, 5] making this an import-
ant target for intervention.
On average, adults with T2DM spend 8.0-9.5 h/day be-
ing sedentary (i.e. expending minimal amounts of energy
when sitting, reclined or lying down during waking hours)
when measured with accelerometers [6–8]. Sedentary be-
haviour is detrimentally associated with the duration of
hyperglycaemia, waist circumference, insulin resistance
and high-density lipoprotein cholesterol (HDL-C) in
people with T2DM [6, 9]. The associations of sedentary
time with T2DM, CVD and psychological well-being have
been shown to be independent from physical activity
levels [10–12], although 60-75 min/day of moderate-
intensity physical activity may offer protection against the
increased mortality risk associated with high amounts of
sitting [13]. However, this amount of moderate activity
may be an unrealistic target for the majority of the popula-
tion [14]. Reducing daily sitting time is thus an important
target for the prevention of CVD and poor psychological
well-being in ambulatory adults with T2DM [15].
In addition to reducing daily sedentary time, regularly
breaking up prolonged periods of sedentary time with
short bouts of activity is recommended for people with
T2DM [15]. This is largely based on findings from con-
trolled laboratory studies in which breaking up sitting
with 2-5 min of standing, light and moderate-intensity
walking every 20-30 min acutely improved cardiometa-
bolic health in healthy, overweight/obese and T2DM
participants [16–19]. The magnitude of response in such
studies appears to be greatest in individuals with poor
metabolic health, suggesting that participants with
T2DM could benefit most from this type of intervention.
A number of interventions using behaviour change
techniques (BCTs) delivered through means such as
education sessions, wearable devices, height-adjustable
workstations and health coaching have reduced sitting in
the general population and office workers [20, 21].
Multi-component workplace interventions that included
providing information, goal setting, health coaching,
self-monitoring and a height-adjustable workstation re-
duced sitting by 45-83 min per work shift after 12
months [20, 21]. A workplace intervention consisting of
computer-prompt software and phone apps (for self-
monitoring and goal setting), but without provision of
height-adjustable workstations, reduced prolonged sit-
ting by 39 min and increased the number of breaks from
sitting by 7.8 per work shift after 8 weeks [22]. In an 8-
week non-workplace specific intervention, a phone app
that provided information and facilitated self-
monitoring, goal setting and prompts in relation to sit-
ting was found to be acceptable and had preliminary ef-
ficacy for increasing breaks in sitting and improving
metabolic and psychological health [23]. Interventions
incorporating BCTs such as providing information on
health consequences, problem solving, goal setting, ac-
tion planning, social support, restructuring the physical
environment, prompts and cues, and self-monitoring
thus appear to have promise for reducing sitting. How-
ever, there is a paucity of interventions aimed at redu-
cing sitting in people with T2DM.
Tailored behaviour change strategies are more likely to
lead to effective outcomes, as seen when delivering inter-
ventions using motivational interviewing [24, 25] and
those based on self-determination theory [26]. Thus, en-
abling participants to select their own tools (e.g. the
phone app, computer-prompt software or wearable
tracker they use), whilst ensuring that the same BCT
strategy is being delivered (e.g. self-monitoring), may be
a more effective approach to reducing sitting. Although
the findings of the interventions discussed above are
promising, participants in these studies were not pro-
vided a choice with regards to the behaviour change
tools they could use within the intervention. One previ-
ous intervention that comprised of reviewing sitting
time, providing feedback on sitting and allowing partici-
pants to choose six different goals relating to ways to re-
duce sitting, led to a 96 min/day decrease in sitting after
6 weeks in older adults [27]. Interventions aimed at re-
ducing and breaking up sitting in people with T2DM
may thus benefit from using a tailored approach, but this
has not yet been evaluated.
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The primary aim of this study, therefore, is to conduct
a randomised controlled trial (RCT) to assess the feasi-
bility of delivery and evaluating a novel tailored interven-
tion that utilises a standardised set of BCTs to reduce
and break up sitting in ambulatory adults with T2DM.
The main objectives of the study are to establish and re-
fine a recruitment strategy, determine participant attri-
tion and completion rates for the outcome measures,
assess the acceptability of randomisation to intervention
or usual care, acceptability of the intervention and data
collection procedures and intervention fidelity and ad-
herence. The secondary objectives are to derive prelim-
inary estimates of the effect of the intervention on
sitting, physical activity and health-related outcomes.
Methods
Study design and randomisation
This will be a mixed-methods randomised controlled
feasibility trial taking place in England and conducted,
analysed and reported in accordance with the Consolida-
tion Standards of Reporting Trials (CONSORT) state-
ment for pilot and feasibility trials [28]. The study
protocol is reported in line with the Standard Protocol
Items: Recommendations for Interventional Trials (SPIR
IT) statement [29]. After baseline demographic, behav-
ioural- and health-related measures (see below), partici-
pants will be individually randomised to either the
REgulate your SItting Time (RESIT) intervention or
usual care (control group). An independent researcher
will use computer generated lists for randomisation of
participants in a 1:1 (intervention:control) ratio with a
fixed block size of four. The research team and partici-
pants will remain blinded to group allocation but, due to
the nature of the intervention, the participants and re-
search team members who are in direct contact with
them will not be blinded following baseline measures.
Further measurements will be conducted at 12 and 24
weeks after baseline measures. The overall study design
is shown in Fig. 1. The trial is being conducted during
the COVID-19 pandemic. As such, contingency plans
are described below, where relevant, with regards to the
conduct of the trial if face-to-face research activities are
not possible due to restrictions that may be in place be-
cause of the pandemic.
Eligibility criteria
Participants will be eligible if they meet the following in-
clusion criteria:
 Aged 18-85 years.
 Diagnosed with T2DM. This will be confirmed
objectively via a fasting glucose measurement during
baseline data collection. COVID-19 contingency: If it
is not possible to take glucose measures, with
consent, each participant’s General Practitioner (GP)
will be asked to inform the research team if their
patient does not have a T2DM diagnosis.
 Able to ambulate unassisted (with or without the
use of a walking aid).
 Self-report sitting for ≥7 h/day. This threshold was
selected as mortality risk starts to increase above
this volume of daily sitting [30, 31].
Exclusion criteria are as follows:
 Using insulin medication.
 Unable to communicate in English.
 Pregnancy.
 Cognitive or physical conditions interfering with the
ability to stand and ambulate.
Sample size
Sample sizes between 24 and 50 have been recom-
mended for pilot and feasibility studies [32, 33]. A sam-
ple size of 70 will be used in this study. This will be
sufficient to determine the feasibility of delivering and
evaluating the intervention as well as identifying the ac-
tive ingredients of the intervention in which multiple be-
haviour change tools can be selected in various
combinations by the intervention participants. Further-
more, an n of 35 in the intervention group was consid-
ered sufficient for exploring participants’ experiences
with using different combinations of these tools and
whether this was an acceptable intervention approach.
Participant recruitment
Participant recruitment will be via GP practices where
study information will be sent out via postage using
Docmail (CFH Docmail Ltd., Radstock, UK) and via GP
practice SMS text messaging services to potentially eli-
gible patients identified in a database search. NHS re-
cruitment will be supported by the Clinical Research
Network North West London. This is in addition to
recruiting via local Diabetes UK support groups (via
emails sent out of with a participant information sheet
and attendance at group sessions) and social media. A
video about the study developed by Health & Care Inno-
vations (Torquay, UK) will be shared on social media
and made available on the project webpage (tinyurl.com/
RESIT-information). Potentially eligible participants will
be asked to express their interest by email, by returning
a reply slip to the research team, or by scanning a Quick
Response (QR) code provided on recruitment materials
that will take them to the project webpage to complete a
webform. A researcher will then contact interested vol-
unteers by email/telephone to screen them for eligibility.
Individuals who remain potentially eligible will then be
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invited to complete baseline data collection after provid-
ing informed consent.
The RESIT intervention
The RESIT intervention is intended to last 24 weeks.
The intervention was developed following the Medical
Research Council guidelines for developing and evaluating
complex interventions [34]. An evidence base was identified
that supported the need for reducing sedentary behaviour
in people with T2DM. Optimal BCTs and their modes of
delivery for reducing sedentary behaviour in occupational
and non-occupational settings were then identified from
previous systematic reviews and published interventions
[20, 22, 23, 35–39]. The research team discussed the BCTs
and modes of delivery to reach a consensus on those that
would be most appropriate for delivering a community-
based intervention to reduce sitting in people with T2DM,
taking into account factors such as affordability, practicabil-
ity and acceptability. The BCTs that the RESIT intervention
aims to deliver are shown in Table 1. The intervention
strategies include an online education programme, health
coach support and self-selected behaviour change tools.
The use of tailored behaviour change strategies were identi-
fied as an efficacious approach for optimising intervention
outcomes [24–26]. The strategies through which some
BCTs are delivered in this intervention thus vary depending
on the behaviour change tools selected by each participant.
However, it is intended that each participant will receive
Fig. 1 Study design
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the same set of standardised BCTs (Table 1). The RESIT
intervention consists of the following strategies.
Online education programme
After randomisation, all intervention participants will be
provided with an online education programme. This is
an adapted version of the one used in the SMART Work
and Life intervention [40], content of which was based
on the face-to-face education used in the SMArT Work
multicomponent intervention that led to significant reduc-
tions in workplace sitting after 12 months [20]. The online
programme includes numerous interactive modules that
cover information on the health consequences of excessive
sitting, the benefits of reducing sitting, awareness of own
sitting time, goal setting and action planning for reducing
sitting, addressing potential barriers to sitting less and the
importance of self-monitoring and using prompts.
Health coach support
Intervention participants will receive support from a
qualified health coach. The first consultation will take
place 1 to 3 days after completing the online education
programme and will be conducted face-to-face or by
video call. Subsequent sessions will be conducted by
telephone or video call at approximately 2, 6 and 12
weeks after baseline. It is expected that the following
BCTs will be used within the health coaching sessions:
goal setting, problem solving, action planning, review be-
haviour goals, discrepancy between current behaviour
and goal, feedback on behaviour, self-monitoring of be-
haviour, social support-unspecified, information about
antecedents, information about health consequences,
prompts/cues, credible source, pros and cons, social reward
and verbal persuasion about capability. The consultations
will be semi-structured tailored sessions harnessed on the
G.R.O.W (Goal, Reality, Options, Will) model of health
coaching [41] that will take each participant through the
four stages to enhance intrinsic self-determined motivation,
whilst also addressing their capability and opportunity in
line with the COM-B (Capability, Opportunity, Motivation
– Behaviour) system of behaviour change situated at the
hub of the Behaviour Change Wheel [42]. The initial ses-
sion will focus on a discussion around goals, reality (bar-
riers to reducing sitting using a COM-B behavioural
diagnosis), options (self-selected behaviour change tools),
and will (confidence to change, how to action plan, monitor
and reward progress). Health coaches will use the content
of the initial consultation to inform the subsequent coach-
ing sessions, tailored to the participant’s needs and circum-
stances. These sessions will involve reviewing behavioural
goals, problem-solving and progress/adjustment of goals.
Participants will be able to contact health coaches via
email/telephone/video call outside of planned consultations
for additional support if they wish. Each of the health coa-
ches will be trained by the research team to standardise the
method of delivery and BCTs used during the intervention.
Self-selected behaviour change tools
Participants will be able to select the self-monitoring
and prompt tools that they would like to use to support
them in reducing and breaking up their sitting time.
This includes a suite of commercially available smart-
phone apps, computer software and wearable devices
that assess sitting time/inactive time/computer use and
provides feedback and prompts to break up sitting. As
described above, the use of tailored behaviour change
strategies are more likely to lead to effective outcomes
than fully prescribed strategies, as seen when delivering
interventions using motivational interviewing [24, 25]
and those based on self-determination theory [26]. Our
previous intervention work (e.g. the STAND [39], SMArT
Work [20], Beat the Seat [22] and MyHealthAvatar-
Diabetes [23] interventions) has shown that a ‘one size fits
all’ approach is not the most appropriate for achieving re-
ductions in sitting across all participants. Thus, enabling
participants to select their own tools for delivery of the
same BCT strategy (e.g. self-monitoring of behaviour) may
be a more effective approach for reducing sitting.
The self-selected tools will be provided to participants
and/or downloaded onto their phone/computer under
guidance from a research assistant following completion
of the online programme. Participants will be permitted
to choose a maximum of one tool from each of the fol-
lowing categories: (a) smartphone app, (b) computer
software and (c) wearable device; they are not required
to choose a tool from every category if they do not wish
to. For example, a participant may choose a smartphone





Review behaviour goals [1.5]
Discrepancy between current behaviour and goal [1.6]
Feedback on behaviour [2.2]
Self-monitoring of behaviour [2.3]
Social support—unspecified [3.1]
Information about antecedents [4.2]
Information about health consequences [5.1]
Demonstration of the behaviour [6.1]
Prompts/cues [7.1]
Credible source [9.1]
Pros and cons [9.2]
Social reward [10.4]
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app and a wearable device, but not a computer software
tool. The research team will provide a brief guidance
document to the participant for each tool selected that
will explain how to download it (if relevant) and how it
works. Participants will not receive any instructions on
how often they should engage with the tools that they
select in line with the intervention being person-focused.
The chosen behaviour change tools can be changed dur-
ing the intervention period if a participant reports to the
health coach or research team that they are not engaging
with the tool. This might be due to reasons such as tech-
nical complexity, impracticality or a dislike of the tool. If
there are any problems with using any of the tools dur-
ing the intervention, participants will be able to contact
the research team for troubleshooting.
Control group
Participants randomised to this group will continue to
receive their usual diabetes healthcare. They will
complete the same measurements (described below) as
the intervention group. After the trial has concluded,
this group will be offered use of the online education
programme and the self-selected behaviour change tools.
Measurements
After eligibility screening, participants will be invited to
complete baseline data collection. This will include the
collection of demographic information: date of birth,
sex, ethnicity, employment status. The measures below
will be collected at baseline and again 12 and 24 weeks
later. Information on COVID-19 circumstances will also
be collected at each time point including whether partic-
ipants have had COVID-19 (and date of positive test re-
sult if relevant), any changes to employment status (e.g.
not working, shift pattern changes, working from home
or returning to work) and/or periods of self-isolation.
Participants will be required to fast for a minimum of 10
h prior to each data collection session, which will take
place at Brunel University London. At the end of this
session, participants will be provided with an activPAL4
activity monitor (PAL Technologies, Glasgow, Scotland)
to wear for eight days and will return this via post. Each
participant will receive a £10 shopping gift voucher for
each data collection time point if they take part in the
data collection procedures and return the activity moni-
tor to the research team. Data will be entered and man-
aged securely online using Qualtrics (Qualtrics, London,
UK). The Qualtrics platform will also be used by partici-
pants for completing the study questionnaires.
Trial feasibility and intervention acceptability
Trial feasibility will be assessed based on recruitment
and retention rates in addition to missing data rates for
each of the study measurements. Acceptability and
fidelity of the intervention will be assessed as part of the
process evaluation described below.
Expected main outcomes for a full trial
The expected primary outcome in a definitive full trial is
average daily sitting time. The expected secondary out-
comes include behavioural (prolonged sitting time, num-
ber of breaks in sitting, standing time, and steps),
cardiometabolic health, physical function, sleep, muscu-
loskeletal and psychological well-being measures.
Sitting, standing and stepping Sitting, standing and
stepping will be measured using the activPAL4 activity
monitor worn on the thigh for 24 h/day for eight con-
secutive days. The activPAL provides valid and reliable
assessment of sitting, standing, stepping and postural
transitions [43–47]. A diary will be completed by partici-
pants for each day that they wear the activPAL to record
the time they woke up and got out of bed, the time they
went to bed and went to sleep, any times they worked,
and any periods when the device was removed [48]. The
device will be waterproofed using a nitrile sleeve and
medical dressing (Hypafix Hypoallergenic Tape; BSN
Medical Limited, Hull, UK) prior to being attached to
the right thigh using a Hypafix dressing. Participants will
be asked to remove the activPAL when swimming in
case it becomes detached and lost. COVID-19 contin-
gency: the activPAL activity monitors will be issued and
returned exclusively by post.
Body composition, anthropometry and blood
pressure Height will be measured using a stadiometer.
Weight and body fat % will be measured using the
TANITA MC-780MA P segmental body composition
analyser (Tanita Corporation, Tokyo, Japan). This device
provides a reliable and valid estimate of body fat % using
bio-electrical impedance analysis [49]. Participants will
wear lightweight clothing and remove shoes and socks
for this measurement. Body mass index will be calcu-
lated as weight (kg)/height2 (cm). Waist circumference
will be measured using an adjustable tape measure (Seca
201, Seca Ltd, Birmingham, UK) to the nearest 0.1 cm at
the level of the umbilicus at the end of gentle expiration.
Blood pressure will be measured on the right arm in a
seated position using an Omron M5-I automatic moni-
toring device (Omron Corporation, Kyoto, Japan). After
5 min of rest, the first reading will be taken followed by
two further readings with a 2-min rest between each.
The average of the lowest two recordings will be used
for analysis. COVID-19 contingency: Participants will be
asked to measure their waist circumference following
standard protocols during a video call with a researcher.
They will be provided with a Seca 201 tape measure and
receive verbal guidance on how to take the
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measurement. Body fat %, height and weight measure-
ments will not be taken.
Biochemical measures A finger prick technique will be
used to collect fasting capillary blood samples. Glycated
haemoglobin will be analysed using the Quo-Test
HbA1c analyser (EKF Diagnostics, Cardiff, UK). Fasting
total cholesterol, HDL-C, triglycerides and glucose con-
centrations will be determined using the CardioChek PA
point-of-care-system (PTS Diagnostics, Indianapolis,
USA). COVID-19 contingency: These measures will not
be taken if in-person data collection is not possible. In
this scenario participants would not be required to fast
prior to any measurements being taken.
Psychological, sleep, musculoskeletal and well-being
measures Perceived fatigue will be measured using the
Chalder Fatigue Scale [50]. Behaviour-specific self-
efficacy for reducing sitting will be assessed using an
adapted version of the Schwarzer and Renner Physical
Exercise Self-Efficacy Scale [51]. General perceived sense
of control over one’s actions and outcomes will be
assessed using the Generalised Self-Efficacy Scale [52].
The Cohen Perceived Stress Scale will assess perceived
stress [53]. To assess the affective aspect of subjective
well-being, the Positive and Negative Affect Schedule
will measure positive and negative mood [54, 55]. The
World Health Organization Five Well-Being Index will
measure psychological well-being [56] and quality of life
will be measured using the WHOQOL-BREF question-
naire [57]. The Pittsburgh Sleep Quality Index question-
naire will assess sleep quality and duration [58] and
musculoskeletal symptoms will be measured using the
Standardised Nordic Questionnaire [59].
Physical function Physical function will be assessed
using the Short Physical Performance Battery (SPPB)
[60] and hand grip strength. The SPPB includes mea-
sures of standing balance, walking speed and rising from
a chair. Standing balance will be tested using tandem,
semi-tandem and side-by-side stands. For each stand
type, the researcher will first demonstrate the task and
will then support one arm whilst the participant posi-
tions their feet. They will then release support when the
participant is ready and start timing. The timing will
stop when the feet move, the participant grasps the re-
searcher for support, or once 10 s has passed. For the
semi-tandem stand, the heel of one foot is placed to the
side of the first toe of the other foot. If they are unable
to hold this position for 10 s, participants will be
assessed with the feet in the side-by-side position. If the
semi-tandem position is held for 10 s, participants will
also perform the full tandem position with the heel of
one foot directly in front of the toes of the other foot.
Walking speed will be assessed using an 8-foot walking
course with participants instructed to ‘walk to the other
end of the course at your usual speed, just as if you were
walking down the street to go to the store’. The walk is
timed and will be performed twice with the fastest time
used for analysis. For the rising from a chair test, partici-
pants will be instructed to fold their arms and stand up
from a straight-backed chair once. If they perform this
successfully, they will then stand up and sit down as
quickly as possibly five times whilst being timed. Hand
grip strength will be measured on the dominant hand
using a digital hand grip dynamometer (Takei Scientific
Instruments Co., Ltd, Niigata, Japan) whilst in a standing
position with the shoulder adducted and neutrally ro-
tated and the elbow in full extension. Three maximum
attempts will be performed with a 1-min rest between
each and the average recorded [61]. COVID-19 contin-
gency: For the standing balance test, participants will be
advised to do this next to a table for support instead of a
researcher. For walking speed, participants will be asked
to identify an 8-foot clear space where they can perform
the test and will be provided with materials to mark out
an 8-foot distance. The chair sit to stand task will be
performed at home using a chair that can be positioned
steady against a wall. The tests will be completed during
a video call between the participant and a member of
the research team. Grip strength will not be measured.
Process evaluation
The process evaluation will include an assessment of the
number of participants recruited via the different re-
cruitment strategies and reasons for ineligibility and
withdrawal during the trial. Questionnaires and inter-
views will be used to explore how the intervention was
experienced by the participants, the contextual factors
that might affect the implementation and outcomes of
the intervention, any contamination between the study
groups, the implementation fidelity of the trial and inter-
vention and any adaptations that are required to the
intervention. Self-report questionnaires will be com-
pleted by all participants to explore if the data collection
measurements encouraged them to change their behav-
iour. Intervention participants will additionally answer
questions exploring their engagement with the different
intervention components. Semi-structured interviews
will be completed with a subset of intervention partici-
pants to evaluate acceptability of the intervention in
terms of compliance with intervention components, fa-
cilitators and barriers to participation/compliance and
choices made regarding the self-selected behaviour
change tools. Interviews will also assess suitability of
data collection procedures with a subset of control and
intervention participants. Health coaches will be inter-
viewed to assess the feasibility and fidelity of delivering
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the coaching sessions and will be asked to record 30% of
their sessions. These recordings will be used in training
booster sessions to monitor GROW and BCT delivery
and offer additional support to boost fidelity. The inter-
views and recorded coaching sessions will be transcribed
verbatim. Additional contact points with health coaches
outside of planned consultations will also be recorded.
Completion rates for the online education programme
and health coaching sessions will be collected. The num-
ber of times each self-selected behaviour change tool is
chosen, the combinations in which they are chosen, any
switches in these tools made during the intervention and
reasons for the switches will also be recorded and
evaluated.
Cost-effectiveness
Cost-effectiveness of the intervention is intended to be
included in a future full trial. The feasibility of collecting
data to inform a cost-effectiveness evaluation will be ex-
plored in this study. This will include estimating the cost
of the intervention in terms of the required equipment
and resources (e.g. cost of wearable devices, phone apps
and computer software) in addition to the cost of train-
ing and delivery of the health coaching. Quality-adjusted
life-years will also be derived from the WHOQOL-BREF
measure [57].
Data analysis
Participant eligibility rates will be calculated as the num-
ber of participants eligible / number of participants
assessed for eligibility × 100. Recruitment rate will be
calculated as the number of participants randomised /
number of eligible participants screened × 100. Reten-
tion rate for the trial will be calculated as the number of
participants who complete follow up measures / number
of participants enrolled into the study × 100. Comple-
tion rates for the data collection measures will be calcu-
lating as the number of complete datasets for each
outcome measure / number of participants enrolled into
the study × 100.
Interviews will be analysed deductively using Content
Thematic Analysis [62], which will be facilitated using
the NVivo software (QRS International Pty Ltd, Victoria,
Australia). This will enable identification of themes rela-
tive to APEASE criteria of the Behaviour Change Wheel
[42] to explore Affordability (Can it be delivered to
budget?), Practicability (Can it be delivered as de-
signed?), Effectiveness and cost-effectiveness (Does it
work, is it cost-effective?), Acceptability (Is it judged ap-
propriate by relevant stakeholders?), Side-effects/safety
(Does it have any unwanted side-effects or unintended
consequences?), and Equity (Will it reduce or increase
the disparities in health/well-being and can it be
accessed without causing disparity?).
Each intervention strategy and BCT will be scored for
each of the APEASE criteria [63]. Rating scales concern-
ing the intervention will be analysed using descriptive
statistics (means, SD, frequencies) and the open-ended
responses will be used to identify relevant themes that
may explain the quantitative responses provided. The
health coaching session recordings will be coded using
the list of BCTs included in the trial and the Motiv-
ational Interviewing Treatment Integrity scale [64] to as-
sess delivery fidelity. Coders will also listen out for any
additional (unintended) BCTs that may have been used
that were not in the protocol.
Changes in the descriptive data for each of the study
outcome measures will be calculated for the intervention
and control groups to explore preliminary efficacy of the
intervention. Continuous data will be summarised in
terms of mean ± SD. Categorical data will be sum-
marised in terms of frequency, counts and percentages.
All baseline variables will be tabulated by the treatment
allocation and the overall sample. Descriptive summaries
will be generated using SPSS (IBM Corp., Armonk, NY,
USA).
Progression criteria to full trial
The feasibility trial will be deemed successful and lead to
a definitive full trial if the following criteria are met:
 The number of required participants is recruited in
the planned timeframe for this study.
 ≥70% of participants are retained in the study and
provide valid activPAL data at both baseline and
subsequent measurement timepoints.
 The qualitative analysis indicates that the
participants found the intervention to be acceptable.
If these thresholds are not achieved, barriers to partici-
pation and potential adaptations to the study will be ex-
plored to identify if issues can be overcome in a full
trial.
Discussion
Adults with T2DM engage in high amounts of sitting
[6–8], increasing their risk of hyperglycaemia, CVD and
poor psychological well-being [6, 9]. However, there is a
paucity of research that has evaluated the feasibility of
interventions aimed at reducing and breaking up sitting
in ambulatory adults with T2DM. Furthermore, to the
authors’ knowledge, there are no studies that have evalu-
ated the feasibility or effectiveness of a tailored interven-
tion aimed at reducing and breaking up sitting in which
participants with T2DM are able to select their own be-
haviour change tools. This study will thus determine the
feasibility of conducting an RCT of a tailored
Bailey et al. Pilot and Feasibility Studies            (2021) 7:76 Page 8 of 11
intervention to reduce and break up sitting in ambula-
tory adults with T2DM.
The strengths of the study include the robust rando-
mised controlled trial design to explore the feasibility of
conducting an RCT of a tailored intervention to reduce
and break up sitting in adults with T2DM. The system-
atic theory and evidence-driven approach used in the de-
velopment of the intervention is a further strength. In
addition, the embedded process evaluation will identify
how the intervention is experienced by the participants
and health coaches, the contextual factors that affect im-
plementation and any adaptations that may be needed
for a future trial.
The results of the study will enable a decision regard-
ing whether or not a full RCT should be conducted and,
if so, will inform its development so that the effective-
ness and sustainability of a tailored intervention to re-
duce and break up sitting in ambulatory adults with
T2DM can be determined. This feasibility trial will also
provide insight for future studies concerning the promo-
tion of health and well-being in this population group.
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